AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Grant

Awarded By

Total Award Amount

  • 338.00

    • Direct Costs

  • 266.00

    • Sponsor Award Id

  • 9400660000

    • Contributor

  • Ana Xavier   Investigator  
  • Christina Bemrich-Stolz   Investigator  
  • Elizabeth Alva   Investigator  
  • Gregory Friedman M.D.   Investigator  
  • Jeffrey Lebensburger   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Lee Hilliard   Investigator  
  • Matthew Kutny M.D.   Investigator  
  • Smita Bhatia M.D.   Investigator